Our two extended half-life factor replacement therapies for people with
hemophilia A and B were launched in 2014, becoming the
first innovations in hemophilia management in almost 20 years, and we remain
committed to the hemophilia community.
We launched the first and only FDA approved treatment for acquired
thrombotic thrombocytopenic purpura (aTTP).
We pioneered the first and
only FDA approved treatment for cold agglutinin disease (CAD).